Table 2.
Descriptions of the three study cohorts according to bisphosphonate use
|
MarketScan (US) |
Ingenix (US) |
THIN (UK) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALN or RIS | ALN | RIS | Nonusers | ALN or RIS | ALN | RIS | Nonusers | ALN or RIS | ALN | RIS | Nonusers | |
| Total, N | 95,228 | 59,026 | 36,202 | 352,627 | 33,907 | 21,241 | 12,666 | 122,196 | 14,958 | 11,047 | 3,911 | 54,847 |
| Age at index, median | 64 | 63 | 65 | 64 | 60 | 60 | 60 | 60 | 72 | 72 | 73 | 71 |
| Total PY of FU | 144,991 | 92,582 | 52,409 | 599,349 | 45,881 | 28,848 | 17,033 | 198,017 | 28,613 | 21,508 | 7,105 | 120,167 |
| AF cases, N | 1,480 | 903 | 577 | 6,521 | 356 | 251 | 105 | 1,628 | 159 | 127 | 32 | 658 |
| AF incidence/1,000 PY | 10.2 | 9.8 | 11.0 | 10.9 | 7.8 | 8.7 | 6.2 | 8.2 | 5.6 | 5.9 | 4.5 | 5.5 |
| AF cases (hospital) | 328 | 1,580 | 208 | 1,064 | 11 | 40 | ||||||
| AF cases (ECG) | 913 | 4,099 | 212 | 1,053 | 10 | 55 | ||||||
| Any dysrrhythmia, Na | 5,965 | 3,676 | 2,289 | 23,181 | 1,577 | 1,000 | 577 | 6,682 | 515 | 401 | 114 | 1,849 |
| Days of FU, median | 519 | 539 | 487 | 603 | 441 | 441 | 442 | 574 | 746 | 777 | 677 | 895 |
| # of all Rx, median | 28 | 27 | 31 | 29 | 22 | 21 | 23 | 19 | 44 | 42 | 50 | 28 |
| # of BIS Rx, median | 5 | 5 | 4 | NA | 5 | 5 | 5 | NA | 9 | 9 | 8 | NA |
| Weekly regimen, % | 96.9 | 97.1 | 96.6 | NA | 97.3 | 97.5 | 96.8 | NA | 92.8 | 96.6 | 82.1 | NA |
| Baseline medical history %* | ||||||||||||
| Angina | 2.4 | 2.3 | 2.7 | 2.7 | 1.9 | 1.7 | 2.0 | 2.0 | 2.3 | 2.2 | 2.4 | 2.1 |
| CHF | 2.3 | 2.1 | 2.5 | 2.7 | 1.4 | 1.3 | 1.4 | 2.1 | 1.0 | 0.9 | 1.3 | 0.7 |
| Diabetes | 9.8 | 9.4 | 10.6 | 14.7 | 8.6 | 8.5 | 8.9 | 14.4 | 4.4 | 4.2 | 5.0 | 6.4 |
| Hospitalization | 14.4 | 14.0 | 15.0 | 13.8 | 9.3 | 9.2 | 9.3 | 9.4 | 9.9 | 10.1 | 9.4 | 5.9 |
| Hypertension | 40.8 | 39.9 | 42.4 | 44.7 | 39.3 | 38.7 | 40.1 | 47.0 | 16.2 | 16.2 | 16.3 | 16.5 |
| Osteoporosis | 40.3 | 40.3 | 40.4 | 7.2 | 44.5 | 44.0 | 45.2 | 8.8 | 22.8 | 22.1 | 24.5 | 0.6 |
| Other heart diseases | 8.4 | 7.9 | 9.1 | 7.9 | 6.8 | 6.6 | 7.1 | 6.7 | 2.6 | 2.5 | 2.9 | 2.1 |
| Renal disease | 0.5 | 0.5 | 0.5 | 0.7 | 0.4 | 0.4 | 0.4 | 0.7 | 0.6 | 0.6 | 0.6 | 0.5 |
| Stroke | 3.9 | 3.7 | 4.3 | 3.8 | 2.1 | 2.0 | 2.2 | 2.1 | 0.8 | 0.8 | 0.9 | 0.7 |
| Thrombosis | 2.3 | 2.2 | 2.4 | 2.1 | 1.7 | 1.8 | 1.7 | 1.6 | 2.0 | 1.9 | 2.3 | 1.5 |
| Baseline drug history, %* | ||||||||||||
| ACE inhibitors | 16.0 | 15.5 | 16.8 | 17.6 | 12.4 | 12.5 | 12.4 | 14.0 | 14.8 | 14.5 | 15.9 | 15.8 |
| Anticoagulants | 2.6 | 2.5 | 2.7 | 2.5 | 1.4 | 1.3 | 1.4 | 1.2 | 2.0 | 1.9 | 2.3 | 1.3 |
| ARB | 7.4 | 7.0 | 8.0 | 8.7 | 4.9 | 4.7 | 5.3 | 5.4 | 5.9 | 5.6 | 6.8 | 5.8 |
| Beta-blockers | 9.4 | 9.0 | 10.0 | 10.5 | 7.1 | 7.3 | 6.8 | 7.6 | 19.0 | 18.5 | 20.5 | 21.2 |
| Ca2+-channel blockers | 15.8 | 15.2 | 16.8 | 18.2 | 11.5 | 11.5 | 11.5 | 12.5 | 17.1 | 16.6 | 18.7 | 16.6 |
| Diuretics | 25.6 | 24.7 | 27.1 | 31.3 | 19.8 | 19.7 | 20.0 | 23.5 | 33.1 | 32.6 | 34.6 | 33.1 |
| Estrogens | 31.4 | 31.6 | 31.1 | 26.4 | 31.7 | 31.1 | 32.8 | 25.6 | 18.4 | 18.9 | 17.1 | 11.9 |
| Anti-ischemic drugs | 4.2 | 4.0 | 4.6 | 4.9 | 2.2 | 2.2 | 2.2 | 2.3 | 8.6 | 8.4 | 9.2 | 7.0 |
| Statins | 29.4 | 28.5 | 30.8 | 28.0 | 22.9 | 22.7 | 23.3 | 19.9 | 15.6 | 14.8 | 17.9 | 15.7 |
Notes:
a
Including atrial fibrillation, any other cardiac dysrrhythmia, or prescriptions for amiodarone;
*
P-values all <0.001 with few exceptions.
Abbreviations: ACE, angiotensin converting enzyme; AF, atrial fibrillation; ALN, alendronate; ARB, angiotensin receptor blockers; BIS, bisphosphonate; CHF, congestive heart failure; FU, follow-up; NA, not applicable; PY, person-years; RIS, risedronate; Rx, prescriptions.